Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism
Antipsychotic drugs (APs) have profoundly changed the treatment landscape for psychiatric disorders, yet their impact on neuroplasticity and neurotrophism remains only partially understood. While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their pred...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/15/3/391 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850280174943207424 |
|---|---|
| author | Federico Mucci Alessandro Arone Riccardo Gurrieri Francesco Weiss Gerardo Russomanno Donatella Marazziti |
| author_facet | Federico Mucci Alessandro Arone Riccardo Gurrieri Francesco Weiss Gerardo Russomanno Donatella Marazziti |
| author_sort | Federico Mucci |
| collection | DOAJ |
| description | Antipsychotic drugs (APs) have profoundly changed the treatment landscape for psychiatric disorders, yet their impact on neuroplasticity and neurotrophism remains only partially understood. While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their predecessors, the emergence of third-generation antipsychotics (TGAs)—such as brexpiprazole, cariprazine, lurasidone, iloperidone, lumateperone, pimavanserin, and roluperidone—has prompted renewed interest in their potential neuroprotective and pro-cognitive effects. This review attempts to carefully examine the evidence on the neurotrophic properties of TGAs and their role in modulating brain plasticity by analyzing studies published between 2010 and 2024. Although data remain limited and focused primarily on earlier SGAs, emerging findings suggest that some TGAs may exert positive effects on neuroplastic processes, including the modulation of brain-derived neurotrophic factors (BDNFs) and synaptic architecture. However, robust clinical data on their long-term effects and comparative efficacy are lacking; therefore, further research is necessary to validate their role in preventing neurodegenerative changes and improving cognitive outcomes in patients with psychiatric conditions. |
| format | Article |
| id | doaj-art-0831e0984b78445da8f36f25eba2e6f8 |
| institution | OA Journals |
| issn | 2075-1729 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-0831e0984b78445da8f36f25eba2e6f82025-08-20T01:48:52ZengMDPI AGLife2075-17292025-03-0115339110.3390/life15030391Third-Generation Antipsychotics: The Quest for the Key to NeurotrophismFederico Mucci0Alessandro Arone1Riccardo Gurrieri2Francesco Weiss3Gerardo Russomanno4Donatella Marazziti5Department of Psychiatry, Lucca Zone, Azienda USL Toscana Nord Ovest, 55100 Lucca, ItalyDepartment of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, 56100 Pisa, ItalyDepartment of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, 56100 Pisa, ItalyDepartment of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, 56100 Pisa, ItalyDepartment of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, 56100 Pisa, ItalyDepartment of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, 56100 Pisa, ItalyAntipsychotic drugs (APs) have profoundly changed the treatment landscape for psychiatric disorders, yet their impact on neuroplasticity and neurotrophism remains only partially understood. While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their predecessors, the emergence of third-generation antipsychotics (TGAs)—such as brexpiprazole, cariprazine, lurasidone, iloperidone, lumateperone, pimavanserin, and roluperidone—has prompted renewed interest in their potential neuroprotective and pro-cognitive effects. This review attempts to carefully examine the evidence on the neurotrophic properties of TGAs and their role in modulating brain plasticity by analyzing studies published between 2010 and 2024. Although data remain limited and focused primarily on earlier SGAs, emerging findings suggest that some TGAs may exert positive effects on neuroplastic processes, including the modulation of brain-derived neurotrophic factors (BDNFs) and synaptic architecture. However, robust clinical data on their long-term effects and comparative efficacy are lacking; therefore, further research is necessary to validate their role in preventing neurodegenerative changes and improving cognitive outcomes in patients with psychiatric conditions.https://www.mdpi.com/2075-1729/15/3/391neuroplasticityneurotrophismthird-generation antipsychoticsbrexpiprazolecariprazinelurasidone |
| spellingShingle | Federico Mucci Alessandro Arone Riccardo Gurrieri Francesco Weiss Gerardo Russomanno Donatella Marazziti Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism Life neuroplasticity neurotrophism third-generation antipsychotics brexpiprazole cariprazine lurasidone |
| title | Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism |
| title_full | Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism |
| title_fullStr | Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism |
| title_full_unstemmed | Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism |
| title_short | Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism |
| title_sort | third generation antipsychotics the quest for the key to neurotrophism |
| topic | neuroplasticity neurotrophism third-generation antipsychotics brexpiprazole cariprazine lurasidone |
| url | https://www.mdpi.com/2075-1729/15/3/391 |
| work_keys_str_mv | AT federicomucci thirdgenerationantipsychoticsthequestforthekeytoneurotrophism AT alessandroarone thirdgenerationantipsychoticsthequestforthekeytoneurotrophism AT riccardogurrieri thirdgenerationantipsychoticsthequestforthekeytoneurotrophism AT francescoweiss thirdgenerationantipsychoticsthequestforthekeytoneurotrophism AT gerardorussomanno thirdgenerationantipsychoticsthequestforthekeytoneurotrophism AT donatellamarazziti thirdgenerationantipsychoticsthequestforthekeytoneurotrophism |